Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: the data collection on adverse events of anti-HIV…

By S. Worm, C. Sabin, R. Weber, P. Reiss, W. El-Sadr, F. Dabis, S. De Wit, M. Law, A. Monforte, N. Friis‐Møller and 5 more. Journal of Infectious Diseases, 2010

681 citations recorded by the source corpus.

Subfields: Political Science and International Relations, Sociology and Political Science

View Paper: https://www.semanticscholar.org/paper/7f8259bab67adebe61d9cec867c0e0779782a475

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. M. Thompson
2. J. Aberg
3. H. Günthard
4. J. Hoy
5. C. Benson
6. A. Telenti
7. S. Hammer
8. J. Eron

Citations in the corpus

• Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA panel. (2012, background): “Such associations have not been found for tenofovir, efavirenz, nevirapine, or atazanavir/r.(60,83) Data on CVD risks are not yet available for darunavir/r, raltegravir, rilpivirine, or elvitegravir.”
• Antiretroviral Treatment of Adult HIV Infection2010 Recommendations of the International AIDS Society–USA Panel (2010, background): “associated with an increased risk of cardiovascularevents.(63,64,97) Ifpossible, these drugsarebestavoidedinpatientswithelevatedcardiovascularrisk.”